150 related articles for article (PubMed ID: 11342323)
1. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
O'Dwyer ME; Launder T; Rabkin JM; Nichols CR
Leuk Lymphoma; 2000 Oct; 39(3-4):411-9. PubMed ID: 11342323
[TBL] [Abstract][Full Text] [Related]
2. [Post-transplantation lymphoproliferative disorder in childhood].
Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
Maldonado NI; Cabanillas F; Jaffe ES; Raffeld M; Lozada L
J Clin Oncol; 2011 Aug; 29(22):e658-60. PubMed ID: 21646613
[No Abstract] [Full Text] [Related]
4. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
5. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
6. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Ninan MJ; Datta YH
Am J Hematol; 2010 Aug; 85(8):635-7. PubMed ID: 20578201
[No Abstract] [Full Text] [Related]
8. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
9. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
Zhu K; Chen J; Chen S
Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder of plasma cell type following allogeneic haemopoietic stem cell transplant treated with rituximab.
Getta B; Kwan J
Intern Med J; 2014 Aug; 44(8):821. PubMed ID: 25081050
[No Abstract] [Full Text] [Related]
13. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
van de Glind G; de Graaf S; Klein C; Cornelissen M; Maecker B; Loeffen J
Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive B cell cerebral lymphoma 12 years after sex-mismatched kidney transplantation: post-transplant lymphoproliferative disorder or donor-derived lymphoma?
Phelan PJ; Murphy RK; Farrell M; O'Toole O; Heffernan J; O'Brien D; Breathnach O; Conlon PJ
Nephrol Dial Transplant; 2010 Jun; 25(6):2032-5. PubMed ID: 20348150
[TBL] [Abstract][Full Text] [Related]
15. Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.
Hirokawa M; Kawabata Y; Fujishima N; Yoshioka T; Sawada K
Int J Hematol; 2007 Oct; 86(3):291-2. PubMed ID: 17989001
[No Abstract] [Full Text] [Related]
16. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.
Herman J; Vandenberghe P; van den Heuvel I; Van Cleemput J; Winnepenninckx V; Van Damme-Lombaerts R
J Heart Lung Transplant; 2002 Dec; 21(12):1304-9. PubMed ID: 12490276
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
18. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
[TBL] [Abstract][Full Text] [Related]
19. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
